← Back to Search

Hormone Therapy

DHEA + Exercise for Osteoporosis

N/A
Waitlist Available
Led By Catherine Jankowski, PhD
Research Sponsored by University of Colorado, Denver
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Refusal of standard osteoporosis treatment in women with moderate osteoporosis (BMD t-scores >=-3.0 and =< 2.5)
Non-frail, as determined by short physical performance battery (SPPB) score > 9 (0-12 scale)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 36 weeks
Awards & highlights

Study Summary

This trial is testing whether bone-loading exercise and DHEA supplements can help improve bone health in older women with low or moderate osteoporosis.

Who is the study for?
Women aged 60-85 with low bone mass or moderate osteoporosis, willing to take DHEA or a placebo and participate in an exercise program for 36 weeks. They must have had their last menstrual period at least 5 years ago, be non-smokers, not on certain medications affecting bone metabolism, and able to live in Denver for the study duration.Check my eligibility
What is being tested?
The trial is testing if taking DHEA orally and doing bone-loading exercises can improve musculoskeletal health in older women with low bone density. Participants will either receive DHEA supplements or a placebo while following an exercise regimen.See study design
What are the potential side effects?
Potential side effects of DHEA may include oily skin, hair loss, stomach upset, high blood pressure, changes in menstrual cycle (if applicable), facial hair growth in women, fatigue and nasal congestion.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have refused standard treatments for my moderate osteoporosis.
Select...
I am not considered frail based on a physical performance test.
Select...
I can walk without any help or devices.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~36 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 36 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in lumbar spine aBMD
Secondary outcome measures
Change in Femoral cortical vBMD
Change in Femoral total vBMD
Body Weight Changes
+10 more

Trial Design

3Treatment groups
Active Control
Group I: DHEA onlyActive Control1 Intervention
1 study pill containing 50 mg of DHEA daily for 36 weeks
Group II: Exercise and DHEAActive Control2 Interventions
1 study pill containing 50 mg of DHEA daily for 36 weeks and supervised bone-loading exercise on 3 days per week for 36 weeks.
Group III: Exercise and PlaceboActive Control2 Interventions
1 study pill containing placebo daily for 36 weeks and supervised bone-loading exercise on 3 days per week for 36 weeks.

Find a Location

Who is running the clinical trial?

University of Colorado, DenverLead Sponsor
1,752 Previous Clinical Trials
2,165,447 Total Patients Enrolled
11 Trials studying Osteoporosis
996 Patients Enrolled for Osteoporosis
National Institute on Aging (NIA)NIH
1,692 Previous Clinical Trials
28,027,035 Total Patients Enrolled
22 Trials studying Osteoporosis
12,043 Patients Enrolled for Osteoporosis
Catherine Jankowski, PhDPrincipal InvestigatorUniversity of Colorado, Denver
3 Previous Clinical Trials
78 Total Patients Enrolled
2 Trials studying Osteoporosis
75 Patients Enrolled for Osteoporosis

Media Library

DHEA (Hormone Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT03227458 — N/A
Osteoporosis Research Study Groups: DHEA only, Exercise and DHEA, Exercise and Placebo
Osteoporosis Clinical Trial 2023: DHEA Highlights & Side Effects. Trial Name: NCT03227458 — N/A
DHEA (Hormone Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03227458 — N/A
~21 spots leftby Jun 2025